{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:58:47Z","timestamp":1790873927606,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.endinu.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T09:46:48Z","timestamp":1540288008000},"page":"611-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Recomendaciones de la Sociedad Espa\u00f1ola de Diabetes (SED) para el tratamiento farmacol\u00f3gico de la hiperglucemia en la diabetes tipo 2: Actualizaci\u00f3n 2018"],"prefix":"10.1016","volume":"65","author":[{"given":"Fernando","family":"Gomez-Peralta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Escalada San Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelmiro","family":"Men\u00e9ndez Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Mata Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Ferrer Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patxi","family":"Ezkurra Loiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"\u00c1vila Lachica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Fornos P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Artola Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"\u00c1lvarez-Guisasola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itxaso","family":"Rica Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Girb\u00e9s Borr\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endinu.2018.08.004_bib0340","unstructured":"International Diabetes Federation. Atlas de la DIABETES de la FID. S\u00e9ptima ed: International Diabetes Federation; 2015 [consultado 15 Feb 2018]. Disponible en: https:\/\/www.fundaciondiabetes.org\/upload\/publicaciones_ficheros\/95\/IDF_Atlas_2015_SP_WEB_oct2016.pdf"},{"key":"10.1016\/j.endinu.2018.08.004_bib0345","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2337\/dc11-1162","article-title":"Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: Findings from the National Health Interview Survey","volume":"35","author":"Gregg","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0350","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0355","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.endonu.2013.10.013","article-title":"Do we need new treatments for type 2 diabetes?","volume":"61","author":"Gomez-Peralta","year":"2014","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.endinu.2018.08.004_bib0360","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1134-3230(10)65006-5","article-title":"Recomendaciones para el tratamiento farmacol\u00f3gico de la hiperglucemia en la diabetes tipo2","volume":"26","author":"Men\u00e9ndez Torre","year":"2010","journal-title":"Av Diabetol"},{"key":"10.1016\/j.endinu.2018.08.004_bib0365","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type2 Diabetes. [consultado 20 Sep 2017]. Disponible en: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf"},{"key":"10.1016\/j.endinu.2018.08.004_bib0370","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2213-8587(17)30033-5","article-title":"Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type2 diabetes","volume":"5","author":"Standl","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endinu.2018.08.004_bib0375","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/CIRCULATIONAHA.116.021914","article-title":"Randomized trials to evaluate cardiovascular safety of antihyperglycemic medications: A worthwhile effort?","volume":"134","author":"Steg","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.endinu.2018.08.004_bib0380","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcjd.2016.02.006","article-title":"Pharmacologic management of type2 diabetes: 2016 interim update","volume":"40","year":"2016","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.endinu.2018.08.004_bib0385","first-page":"S64","article-title":"Pharmacologic approaches to glycemic treatment","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0390","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.endinu.2018.08.004_bib0395","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2337\/dc13-2173","article-title":"Empirically establishing blood glucose targets to achieve HbA1c goals","volume":"37","author":"Wei","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0400","first-page":"517.e1","article-title":"Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition","volume":"60","author":"Mezquita-Raya","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.endinu.2018.08.004_bib0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type2 diabetes: A systematic review","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.08.004_bib0410","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2337\/diacare.28.6.1282","article-title":"Improvement of glycemic control in subjects with poorly controlled type2 diabetes: Comparison of two treatment algorithms using insulin glargine","volume":"28","author":"Davies","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0415","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0420","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0425","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/dc08-9026","volume":"32","author":"Skyler","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0430","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type2 diabetes: One-year results of the look AHEAD trial","volume":"30","author":"Pi-Sunyer","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0435","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2337\/dc15-1585","article-title":"The time is right for a new classification system for diabetes: Rationale and implications of the beta-cell-centric classification schema","volume":"39","author":"Schwartz","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0440","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: an update","volume":"137","author":"Kirpichnikov","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0445","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1464-5491.2010.03098.x","article-title":"Metformin action on AMP-activated protein kinase: A translational research approach to understanding a potential new therapeutic target","volume":"27","author":"Boyle","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0450","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.diabres.2017.07.015","article-title":"Metformin treatment significantly enhances intestinal glucose uptake in patients with type2 diabetes: Results from a randomized clinical trial","volume":"131","author":"Koffert","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 1","key":"10.1016\/j.endinu.2018.08.004_bib0455","first-page":"S73","article-title":"Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0460","doi-asserted-by":"crossref","first-page":"e1001204","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type2 diabetes: A meta-analysis of randomised controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0465","first-page":"34","article-title":"Consensus document on treatment of type2 diabetes in patients with chronic kidney disease","volume":"34","author":"Gomez-Huelgas","year":"2014","journal-title":"Nefrologia"},{"key":"10.1016\/j.endinu.2018.08.004_bib0470","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study","volume":"101","author":"Aroda","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endinu.2018.08.004_bib0475","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.endinu.2018.08.004_bib0480","doi-asserted-by":"crossref","first-page":"e000059","DOI":"10.1136\/bmjdrc-2014-000059","article-title":"Durability of oral hypoglycemic agents in drug naive patients with type2 diabetes: Report from the Swedish National Diabetes Register (NDR)","volume":"3","author":"Ekstrom","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0485","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","article-title":"Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis","volume":"56","author":"Hirst","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.endinu.2018.08.004_bib0490","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/01.CIR.0000134501.57864.66","article-title":"Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type2 diabetes mellitus","volume":"110","author":"Esposito","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.endinu.2018.08.004_bib0495","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type2 diabetes: A systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0500","unstructured":"Canadian Agency for Drugs and Technologies in Health. Canadian New Drugs for Type2. Diabetes: Second-Line. Therapy \u2014 Science Report- 05-2017 [consultado 15 Feb 2018]. Disponible en: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/TR0012_T2DM_Final_Recommendations.pdf"},{"key":"10.1016\/j.endinu.2018.08.004_bib0505","first-page":"CD003639","article-title":"Alphaglucosidase inhibitors for type2 diabetes mellitus","volume":"2","author":"Van de Laar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.endinu.2018.08.004_bib0510","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Non-alcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.endinu.2018.08.004_bib0515","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0520","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0525","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0530","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rce.2017.12.003","article-title":"Treatment of type 2 diabetes mellitus in elderly patients","volume":"218","author":"Gomez-Huelgas","year":"2018","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.endinu.2018.08.004_bib0535","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsboll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.endinu.2018.08.004_bib0540","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0545","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S2213-8587(16)30214-5","article-title":"Renoprotection in LEADER and EMPA-REG OUTCOME","volume":"4","author":"Muskiet","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endinu.2018.08.004_bib0550","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0555","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0560","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc12-2713","article-title":"A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?","volume":"36","author":"Butler","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0565","doi-asserted-by":"crossref","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type2 diabetes: A systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.endinu.2018.08.004_bib0570","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.08.004_bib0575","doi-asserted-by":"crossref","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.endinu.2018.08.004_bib0580","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0585","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.endinu.2018.08.004_bib0590","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endinu.2018.08.004_bib0595","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0600","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s13300-017-0277-0","article-title":"Practical approach to initiating SGLT2 inhibitors in type2 diabetes","volume":"8","author":"Gomez-Peralta","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.endinu.2018.08.004_bib0605","unstructured":"Administration UFaD. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [consultado 15 May 2015). Disponible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm"},{"key":"10.1016\/j.endinu.2018.08.004_bib0610","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1463-1326.2011.01552.x","article-title":"Weight change in people with type2 diabetes: Secular trends and the impact of alternative antihyperglycaemic drugs","volume":"14","author":"Morgan","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.08.004_bib0615","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0620","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.08.004_bib0625","first-page":"CD005613","article-title":"Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type2 diabetes mellitus","author":"Horvath","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.endinu.2018.08.004_bib0630","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type2 and type1 diabetes: A pre-planned meta-analysis of phase3 trials","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.08.004_bib0635","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/dom.12485","article-title":"Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: Glycaemic control and hypoglycaemia with new insulin glargine 300U\/ml versus glargine 100U\/ml in people with type2 diabetes","volume":"17","author":"Ritzel","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.08.004_bib0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.endinu.2018.01.002","article-title":"Consenso sobre tratamiento con insulina en la diabetes tipo2","author":"Girb\u00e9s Borr\u00e1s","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.endinu.2018.08.004_bib0645","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","article-title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type2 diabetes: A systematic review and meta-analysis","volume":"384","author":"Eng","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.endinu.2018.08.004_bib0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2010.08.006","article-title":"Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type2 diabetes: A systematic review","volume":"92","author":"Giugliano","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endinu.2018.08.004_bib0655","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc16-0917","article-title":"Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.08.004_bib0660","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endinu.2018.08.004_bib0665","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.endinu.2018.08.004_bib0670","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016418301940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016418301940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T10:18:32Z","timestamp":1542277112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530016418301940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S2530016418301940"],"URL":"https:\/\/doi.org\/10.1016\/j.endinu.2018.08.004","relation":{},"ISSN":["2530-0164"],"issn-type":[{"value":"2530-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones de la Sociedad Espa\u00f1ola de Diabetes (SED) para el tratamiento farmacol\u00f3gico de la hiperglucemia en la diabetes tipo 2: Actualizaci\u00f3n 2018","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEEN y SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}